advanced breast cancer after disease progression on nonsteroidal aromatase inhibitors (AIs). 3 - 5 For instance, the phase III SoFEA trial revealed that combining fulvestrant with exemestane was no better than either fulvestrant alone or exemestane alone
Search Results
Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel
-free and overall survival. 7 The effectiveness of aromatase inhibitors in the treatment of metastatic breast cancer led to a number of trials incorporating them into the adjuvant therapy of postmenopausal women with early-stage hormone receptor
Kimberly H. Allison
on the ALTERNATIVE trial (examining dual HER2 blockade with lapatinib and trastuzumab + aromatase inhibitor in HER2-positive/hormone receptor–positive metastatic breast cancer), even some of the most recent clinical trial data frequently lack the
Erwei Zeng, Wei He, Karin E. Smedby, and Kamila Czene
), including tamoxifen and/or aromatase inhibitors (AIs), have been proven to reduce breast cancer mortality by approximately 30% for tamoxifen and 40% for AIs for estrogen receptor–positive patients in randomized clinical trials. 4 – 6 However, despite the
Erwei Zeng, Wei He, Karin E. Smedby, and Kamila Czene
tamoxifen and/or aromatase inhibitors (AIs), have been proven to reduce breast cancer mortality by approximately 30% for tamoxifen and 40% for AIs for estrogen receptor–positive patients in randomized clinical trials. 4–6 However, despite the established
Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza
during adjuvant aromatase inhibitor therapy for breast cancer . Clin Cancer Res 2008 ; 14 : 6336 – 6342 . 16. Mincey BA Dentchev T Sloan JA . N03CC—a randomized, controlled, open-label trial of upfront vs. delayed zoledronic acid for
William J. Gradishar, Benjamin O. Anderson, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Robert S. Miller, Mark Pegram, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead, and Rashmi Kumar
breast cancer should be treated similarly to postmenopausal women, except that the use of aromatase inhibitors is ineffective without concomitant suppression of testicular steroidogenesis. 22 , 23 Patient preference is a major component of the decision
Erin Currin, Lanell M. Peterson, Erin K. Schubert, Jeanne M. Link, Kenneth A. Krohn, Robert B. Livingston, David A. Mankoff, and Hannah M. Linden
promising data emerging regarding aromatase inhibitors 9 and concern about endometrial side effects, she was switched from tamoxifen to anastrozole after a year of treatment. The patient experienced a sustained response to endocrine therapy for 1.5 years
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars
, patient age, and menopausal status. Breast cancer does occur in men, and treatment should be similar to that for postmenopausal women, except that aromatase inhibitors are ineffective without concomitant suppression of testicular steroidogenesis. 27 , 28
Harold J. Burstein
direct bearing on the treatment plans for breast cancer survivors. These include data on switching endocrine therapies between years 2 and 3 after diagnosis; use of extended adjuvant endocrine therapy with aromatase inhibitors; introduction of adjuvant
